Abaloparatide vs TB-500
Extensively Studied vs Well Studied
compatible Different mechanisms; no known interactions.
Molecular Data
Abaloparatide TB-500
Weight 3,960 Da 4,963.44 Da
Half-life ~1.7 hours ~2 hours
Chain 34 amino acids 43 amino acids
Type Synthetic PTHrP analog Thymosin fragment
Key Benefits
Abaloparatide
01 FDA-approved for osteoporosis treatment
02 Actively builds new bone (anabolic mechanism)
03 Superior hip BMD gains vs teriparatide in trials
04 Reduces vertebral fracture risk significantly
05 Reduces nonvertebral fracture risk
06 Lower hypercalcemia risk than teriparatide
07 Works through selective PTH1R activation
08 Benefits seen within 6 months
TB-500
01 Superior systemic tissue repair
02 Accelerated muscle, tendon, and ligament healing
03 Enhanced cell migration and angiogenesis
04 Comprehensive regenerative effects
05 Neuroprotective properties
Dosing Protocols
Abaloparatide
80 mcg / Once daily
Osteoporosis treatment 80 mcg Once daily
TB-500
2-5mg per injection (higher doses for serious injuries) / 2-3x weekly (e.g., Monday, Wednesday, Friday)
General tissue repair 2-3mg 2x weekly
Serious injury recovery 4-5mg 3x weekly
Athletic enhancement 2-3mg 2x weekly
Chronic conditions 3-4mg 2-3x weekly
Maintenance 2mg 1-2x weekly
Post-surgical recovery 3-5mg 3x weekly
Side Effects
Abaloparatide
Hypercalciuria (high calcium in urine)
Dizziness
Nausea
Headache
Palpitations
Fatigue
Upper abdominal pain
Vertigo
Injection site reactions
TB-500
Generally minimal side effects
Possible mild injection site reactions
Temporary fatigue in some users
Contraindications
Paget's disease of bone
Prior external beam or implant radiation therapy to skeleton
Bone metastases or history of skeletal malignancies
Metabolic bone diseases other than osteoporosis
Pre-existing hypercalcemia
Pregnancy or nursing
Cumulative use exceeding 2 years lifetime
Active cancer treatment (due to angiogenic effects)
Pregnancy or breastfeeding
Immunosuppressive medications (consult provider)
WADA prohibited for competitive athletes
Research Evidence
Abaloparatide TB-500
Status Extensively Studied Well Studied
References 4 studies 4 studies
Latest — March 2024
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.